Pharmacokinetic sub-study in the SPIRIT III randomized and controlled trial of XIENCE V® everolimus eluting coronary stent system

Journal of Interventional Cardiology

Volumn 23, Issue 1, 2010, Pages 26-32

  Wang, Qing ^a   Pierson, Wesley ^a   Sood, Poornima ^a   Bol, Cornelis ^b   Cannon, Louis ^c   Gordon, Paul ^d   Saucedo, Jorge ^e   Sudhir, Krishnankutty ^a  

^a ABBOTT VASCULAR   (United States)

^b Kinesis Pharma   (Netherlands)

^c Cardiac and Vascular Research Center of Northern Michigan   (United States)

^d MIRIAM HOSPITAL   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ELUTING STENT; DRUG HALF LIFE; FEMALE; GRAFT REJECTION; HUMAN; IMPLANT; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CONFIDENCE INTERVALS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 76749105239     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00517.x     Document Type: Article

References (19)

1. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative pharmacological properties in vitro and in vivo. Transplantation 1997 64 : 36 42. (Pubitemid 27327197)
2. Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998 30 : 2195 2197.
3. Semsroth S, Stigler RG, Bernecker OY, et al. Everolimus attenuates neoinitimal hyperplasia in cultured human saphenous vein grafts. Eur J Vasc Endovasc Surg 2009 35 : 515 520.
4. Sorbera LA, Leeson PA, Castaner J. SDZ-RAD. Drugs Fut 1999 24 : 22 29.
5. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995 17 : 660 665.
6. Kahan BD, Kaplan B, Lorber MI, et al. Rad in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001 71 : 1400 1406.
7. ® (everolimus) in heart transplantation. J Heart Lung Transplant 2005 24 (Suppl. 4 S185 S190. (Pubitemid 40379796)
8. ® everolimus eluting coronary stent system: A preclinical assessment. J Interv Cardiol 2009 22 (Suppl. 1 28 40.
9. Pirron U, Kovarik JM, Eisen H, et al. Longitudinal pharmacokinetics of everolimus in de novo heart transplant patients and its influence on cyclosporine [abstract no. 06262]. Transplantation 2002 74 (Suppl S211.
10. Eisen HJ. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl. J. Med 2003 349 : 847 858.
11. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 2002 73 : 920 925.
12. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipient based on exposure-effect modeling. Am J Transplant 2004 4 : 2126 2131.
13. Wiemer M, Seth A, Chandra P, et al. Systemic exposure of everolimus after stent implantation: A pharmacokinetic study. Am Heart J 2008 156 : 751-e1 751-e7.
14. Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus (Certican): Optimizing dose and tolerability. Transplantation 2005 79 (Suppl S80 S84.
15. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998 30 : 2200 2203.
16. Farb A, Michael John BA, Acampado E, et al. Oral everolimus inhibits in-stent neoinitimal growth. Circulation 2002 106 : 2379 2384.
17. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: Are human and animal studies comparable. Heart 2003 89 : 133 138.
18. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008 299 : 1903 1913.
19. ® everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009 119 : 680 686.